Sansure Biotech Inc (688289)

Currency in CNY
22.31
+0.26(+1.18%)
Closed·

688289 Financial Summary

Key Ratios

P/E Ratio43.46
Price/Book1.66
Debt / Equity11.36%
Return on Equity3.12%
Dividend Yield2.35%
EBITDA267.89M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
* In Millions of CNY (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.49%
Dividend Yield
2.35%
Industry Median 1.85%
Annualised payout
0.53
Paid unevenly
5-Years Growth
-
Growth Streak

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 24.45
(+9.59% Upside)

Earnings

Latest Release
Apr 28, 2025
EPS / Forecast
0.16 / --
Revenue / Forecast
475.49M / --
EPS Revisions
Last 90 days

FAQ

What were Sansure Biotech's earnings for the latest quarter?

The Sansure Biotech EPS (TTM) is 0.49. Sansure Biotech reported sales of 475.49, net income of 91.74, and EPS of 0.16 for the latest quarter.

What was Sansure Biotech's net income for the latest quarter?

Sansure Biotech's net income for the latest quarter was 91.74.

How did Sansure Biotech's performance compare year-over-year in the latest quarter?

The company's revenue moved from 425.48 in the previous quarter to 475.49 in the latest quarter, and net income moved from 80.17 to 91.74 compared to the previous quarter.

What is Sansure Biotech's net profit margin on a TTM basis?

Sansure Biotech's trailing twelve months (TTM) net profit margin is 18.90%.

How does Sansure Biotech's debt to equity ratio compare to industry standards?

Sansure Biotech's total debt-to-equity ratio is 11.36%.

What is Sansure Biotech's return on investment on a TTM basis?

Sansure Biotech's trailing twelve months (TTM) return on investment (ROI) is 3.12%.

Did Sansure Biotech gain or lose cash last quarter?

In the latest quarter, Sansure Biotech's net change in cash was -212.99 million.

What were Sansure Biotech's total assets and liabilities in the latest quarter?

As of the latest quarter, Sansure Biotech reported total assets of 9,684.30 million and total liabilities of 1,301.24 million.

How has Sansure Biotech's total revenue grown this year?

Sansure Biotech's total revenue was 425.48 in the previous quarter and 475.49 in the latest quarter.

What is Sansure Biotech's gross margin on a TTM basis?

Sansure Biotech's trailing twelve months (TTM) gross margin is 79.48%.

What was Sansure Biotech's revenue per share for the latest quarter?

Sansure Biotech's revenue per share for the latest quarter was 6.46.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.